Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective, Randomized, Controlled, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin to Prevent Biliary Complications After ABO Incompatible Adult to Adult Living Donor Liver Transplantation

NCT05666453 is registered in ClinicalTrials.gov with SK Plasma Co., Ltd. as lead sponsor.

NCT NCT05666453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05666453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective, Randomized, Controlled, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin to Prevent Biliary Complications After ABO Incompatible Adult to Adult Living Donor Liver Transplantation
Lead sponsor
SK Plasma Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
April 25, 2022
Completion date
July 1, 2024
Enrollment
59 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

liver transplantation